SurVaxM is under clinical development by MimiVax and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect SurVaxM’s likelihood of approval (LoA) and phase transition for Anaplastic Astrocytoma took place on 10 May 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
In addition, the same event on 10 May 2022 increased SurVaxM’s Phase Transition Success Rate (PTSR) for Oligodendroglioma.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their SurVaxM Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
SurVaxM is under development for the treatment of glioblastoma, brain cancer, recurrent gioblastoma, high grade glioma, multiple myeloma, neuroendocrine tumors including neuroendocrine gastroenteropancreatic tumors and pediatric medulloblastoma, glioblastoma multiforme, anaplastic astrocytoma, high-grade astrocytoma, anaplastic oligodendroglioma, anaplastic ependymoma, ependymoma and diffuse intrinsic pontine gliomas. The vaccine candidate is administered through subcutaneously. SVN53-67/M57-KLH is a peptide vaccine containing a 15-mer peptide with C to M modification at the amino acid position 57. It is derived from the anti-apoptosis protein survivin. It is conjugated with keyhole limpet hemocyanin (KLH).
It was under development for the treatment of autoimmune diseases.
MimiVax operates as a pharmaceutical company that discovers and develops immunotherapeutic vaccines and targeted therapies for the treatment of cancer. The company’s lead candidate is SurVaxM. Its SurVaxM is a cancer vaccine that stimulates a potent immune response and the survivin molecule and an important cellular protein that sustains the viability of tumor cells and can be delivered through a simple injection. MimiVax’s SurVaxM is under clinical trials in recurrent glioma and newly diagnosed glioblastoma; prolongs survival in pre-clinical models of ovarian, brain, renal and prostate cancers. survivin is a cell-survival protein that is present in most cancer and rarely detectable in normal tissue and immunotherapeutic vaccine demonstrate safety and tolerability in a phase. MimiVax is headquartered in Buffalo, New York, the US.
Quick View SurVaxM LOA Data
|Highest Development Stage|